Saturday, June 9

SIMULTANEOUS SESSIONS I

08:00 - 09:15 hours, Room: Mozart I CHRONIC MYELOID LEUKEMIA - CLINICAL I

Chairs: G. Rosti (University of Bologna, Bologna, Italy) A. Hochhaus (University of Heidelberg, Heidelberg, Germany) 08:00 - 08:15

0356 EFFICACY OF DASATINIB IN CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA PATIENTS AFTER IMATINIB FAILURE ACCORDING TO BASELINE BCR-ABL MUTATIONS

M.C. Mueller, S. Branford, J. Radich, N. Shah, P. Erben, T. Ernst, M. Acevedo, C. Nicaise, T. Hughes, A. Hochhaus (Universitaetsklinikum Mannheim, Mannheim, Germany) 08:15 - 08:30

0357 CYTOGENETIC RESPONSE AND DISCONTINUATIONS FROM IRIS STUDY WITH LONG-TERM IMATINIB THERAPY (IM) IN NEWLY DIAGNOSED PH+ CHRONIC MYELOGENOUS LEUKEMIA (PH+CML)

F. Guilhot, B. Druker, S.G. O'Brien, R. Larson (Clinical Research Centre, Poitiers, France) 08:30 - 08:45

0358 DASATINIB INDUCES DURABLE CYTOGENETIC RESPONSES IN PATIENTS WITH CHRONIC-PHASE CML WITH RESISTANCE OR INTOLERANCE TO IMATINIB: UPDATED RESULTS OF THE CA180013 (START-C) TRIAL

F. Guilhot, J. Apperley, T. Facon, D. Niederwieser, C. Gambacorti, T. Fischer, A. Countouriotis, R. Ezzeddine, A. Hochhaus (CHU La Miletrie, Poitiers, France) 08:45 - 09:00

0359 DASATINIB DOSE AND SCHEDULE OPTIMIZATION IN CHRONICPHASE CML RESISTANT OR INTOLERANT TO IMATINIB: RESULTS FROM A RANDOMIZED PHASE-III TRIAL (CA180034)

A. Hochhaus, D.W. Kim, P. Rousselot, H.M. Kantarjian, A. Charbonnier, D. Heim, N. Khoroshko, E. Bleickardt, S. Francis, N.P. Shah (University Heidelberg, Heidelberg, Germany) 09:00 - 09:15

0360 DASATINIB IS SAFE AND EFFECTIVE IN PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC MYELOGENOUS LEUKEMIA (CML) IN CHRONIC PHASE (CML-CP)

A. Quintas-Cardama, H. Kantarjian, S. O’Brien, D. Jones, G. Borthakur, C. Nicaise, J. Cortes (M.D. Anderson Cancer Center, Houston, USA)

SIMULTANEOUS SESSIONS

08:00 - 09:15 hours, Room: Mozart III

CHRONIC LYMPHOCYTIC LEUKEMIA AND RELATED DISORDERS - CLINICAL

Chairs: E. Montserrat (Hospital Clinic, Barcelona, Spain) T. Robak (Medical University of Lódz, Lódz, Poland) 08:00 - 08:15

0361 MAINTENANCE IMMUNOTHERAPY WITH LOW-DOSE RITUXIMAB IMPROVES OUTCOME IN “HIGH RISK” CHRONIC LYMPHOCYTIC LEUKEMIA

G. Del Poeta, M.I. Del Principe, L. Maurillo, F. Buccisano, P. Niscola, E. Ammatuna, V. Gattei, A. Venditti, P. De Fabritiis, F. Lo-Coco, S. Amadori (University Tor Vergata, Rome, Italy) 08:15 - 08:30

0362 ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION CURES CLL: A RETROSPECTIVE ANALYSIS FROM THE SFGM-TC REGISTRY

M. Michallet, Q.H. Le, N. Raus, J.P. Vernant, F. Nicolini, L. Sutton, J.L. Harousseau, P. Colombat, E. DeConinck, B. Cazin, D. Blaise (Hôpital Edouard Herriot, Lyon, France)

08:30 - 08:45 0363 LENALIDOMIDE (REVLIMID) IS AN ACTIVE AGENT IN RELAPSED AND TREATMENT-REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

A. Ferrajoli, S. O'Brien, S. Faderl, W. Wierda, B. Lee, J. Reuben, E. Schlette, Z. Estrov, M. Keating (University of Texas M.D. Anderson Cancer, Houston, USA) 08:45 - 09:00

0364 CLINICAL EFFICACY OF OXALIPLATIN, FLUDARABINE, CYTARABINE, AND RITUXIMAB COMBINATION THERAPY IN PATIENTS WITH RICHTER’S SYNDROME OR FLUDARABINEREFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF A PHASE I-II CLINICAL TRIAL

A.M. Tsimberidou, W.G. Wierda, W.W. Plunkett, S. O'Brien, T.J. Kipps, J.R. Brown, S. Lerner, H.M. Kantarjian, M.J. Keating (U. T. M. D. Anderson Cancer Center, Houston, USA) 09:00 - 09:15

0365 ERADICATON OF MINIMAL RESIDUAL DISEASE IN CHRONIC LYMPHOCYTIC LEUKEMIA IS ASSOCIATED WITH PROLONGED SURVIVAL. LONG TERM FOLLOW UP OF PATIENTS TREATED WITH ALEMTUZUMAB

H.A. Sayala, P. Moreton, B. Kennedy, G. Lucas, M. Leach, S.M.B. Rassam, A. Haynes, J. Tighe, D. Oscier, C. Fegan, A.C. Rawstron, P. Hillmen (HMDS, Leeds General Infirmary, Leeds, United Kingdom)

SIMULTANEOUS SESSIONS

08:00 - 09:15 hours, Room: Strauss I

STEM CELL TRANSPLANTATION I

Chairs: J. Greil (University Children’s Hospital, Heidelberg, Germany) D. Niederwieser (University of Leipzig, Leipzig, Germany) 08:00 - 08:15

0366 ALLOGENEIC STEM CELL TRANSPLANTATION FROM MATCHED RELATED AND UNRELATED DONORS IN THALASSEMIA MAJOR PATIENTS USING A REDUCED TOXICITY FLUDARABINE BASED REGIMEN

I. Resnick, I. Zilberman, P. Tsirigotis, M. Aker, M.Y. Shapira, M. Bitan, B. Gesundheit, A. Amar, A. Ackerstein, S. Samuel, S. Slavin, R. Or (Hadassah - Hebrew Univ. Medical Center, Jerusalem, Israel) 08:15 - 08:30

0367 THE EUROCHIMERISM CONCEPT FOR A STANDARDIZED APPROACH TO CHIMERISM ANALYSIS FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION

T. Lion, F. Watzinger, S. Preuner, H. Kreyenberg, M. Tilanus, R. De Weger, J. Van Loon, L. De Fries, H. Cavé, C. Acquaviva, M. Lawler, M. Crampe, A. Serra, B. Saglio, F. Colnaghi, B. Biondi, J. Van Dongen, M. Van der Burg, M. González, M. Alcoceba, G. Barbany, M. Hermansson, E. Roosnek, C. Steward, J. Harvey, P. Bader (Children´s Cancer Research Institute, Vienna, Austria) 08:30 - 08:45

0368 LONG–TERM FOLLOW–UP AND SAFETY OF BONE MARROW AND PERIPHERAL BLOOD STEM CELL DONORS: A SINGLE INSTITUTION / DONOR REGISTRY REPORT

M. Stadler, B. Behrens, A. Schmitt-Thomssen, E. Dammann, A. Breithaupt, E Wilkens-Aktürk, M. Eder, K.W. Sykora, R. Blasczyk, M. Robin-Winn, A. Ganser, H.G. Heuft (Hanover Medical School, Hanover, Germany) 08:45 - 09:00

0369 ALLOGENEIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH WALDENSTRÖM’S MACROGLOBULINAEMIA. ANALYSIS OF 106 CASES FROM THE EUROPEAN BONE MARROW REGISTRY (EBMT)

C. Kyriakou, C. Kyriakou, C. Canals, G. Taghipour, J. Cornelissen, R. Willemze, G. Socie, K. Thompson, H. Greinix, J. Harousseau, N. Ifrah, J. Kienast, R. Hamladji, M. Kazmi,, P. Jacobs, A. Sureda,, N. Schmitz (University College London, London, United Kingdom) 09:00 - 09:15

0370 HEMATOPOIETIC STEM CELL TRANSPLANTATON FOR OSTEOPETROSIS

P.J. Orchard, M. Eapen, J. Tolar, E. Horwitz, P. Veys, F. Fasth (University of Minnesota, Minneapolis, USA)

SIMULTANEOUS SESSIONS

08:00 - 09:15 hours, Room: Strauss II

ACUTE LYMPHOBLASTIC LEUKEMIA - CLINICAL

Chairs: R. Pieters (Erasmus Medical Center, Rotterdam, The Netherlands) H. Gadner (St. Anna Kinderspital, Vienna, Autria) 08:00 - 08:15

0371 HIGH INTERLEUKIN-15 EXPRESSION LEVELS IN INITIAL DIAGNOSTIC LEUKEMIC CELLS OF CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA ARE ASSOCIATED WITH SUBSEQUENT RELAPSE INVOLVING THE CENTRAL NERVOUS SYSTEM

G. Cario, S. Izraeli, A. Teichert, P. Rhein, J. Skokowa, A. Möricke, M. Zimmermann, A. Schrauder, W.D. Ludwig, K. Welte, H. Schünemann, B. Schlegelberger, M. Schrappe, M. Stanulla (University Hospital Schleswig-Holstein, Kiel, Germany) 08:15 - 08:30

0372 FINAL RESULTS OF THE TREATMENT OF ADOLESCENTS AND YOUNG ADULTS WITH STANDARD-RISK ALL WITH THE PEDIATRIC-BASED PROTOCOL PETHEMA ALL-96

J.M. Ribera, J.M. Ribera, A. Oriol, M.A. Sanz, P. Fernandez-Abellan, E. Del Potro, E. Abella, J. Bueno, C. Grande, C. Calvo, C. Bethencourt, J. Fernandez-Calvo, J.M. Martí, I. Heras, R. Parody, E. Feliu, J.J. Ortega (Institut Català d'Oncologia- Hospital Ge, Badalona, Spain) 08:30 - 08:45

0373 TWO DECADES OF PROGRESSM IN ADOLESCENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIAS TREATED IN THE FRALLE PROTOCOLS: ADOLESCENCE IS NO MORE A BAD PROGNOSTIC FEATURE IF AN INTENSIVE CHEMOTHERAPY IS APPLIED

A. Baruchel, M.F. Auclerc, Y. Perel, F. Mechinaud, A. Auvrignon, C. Schmitt, C. Piguet, O. Lejars, C. Berthou, F. Demeocq, P. Schneider, V. Gandemer, G. Michel, J.M. Cayuela, T. Leblanc, G. Leverger, F. Fralle Group (AP-HP, Paris 7 University, Paris, France) 08:45 - 09:00

0374 RISK ADAPTED TREATMENT OF ADOLESCENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) ACCORDING THE GERMAN MULTICENTER STUDY GROUP (GMALL) STUDIES 06/99 AND 07/03 YIELDS SIGNIFICANTLY DIFFERENT OUTCOME FOR SUBGROUPS

N. Goekbuget, R. Arnold, A. Böhme, R. Fietkau, M. Freund, A. Ganser, M. Kneba, T. Lipp, W.-D. Ludwig, G. Maschmeyer, D. Messerer, H. Rieder, E. Thiel, D. Hoelzer (J.W.Goethe University, Frankfurt Am Main, Germany) 09:00 - 09:15

0375 DIFFERENT OUTGROWTH KINETICS OF CLONES WITH BCR-ABL KINASE DOMAIN MUTATIONS IN DE NOVO VERSUS RELAPSED PHILADELPHIA-POSITIVE (PH+) ALL IMPLY AN ADDITIONAL ROLE OF NON-MUTATIONAL RESISTANCE MECHANISMS

H. Pfeifer, B. Wassmann, S. Wystub, T. Lange, A. Hochhaus, D. Hoelzer, O.G. Ottmann (University Hospital Frankfurt, Frankfurt, Germany)

SIMULTANEOUS SESSIONS

08:00 - 09:15 hours, Room: Strauss III

ANEMIA AND PNH - CLINICAL TRIALS

Chairs: A. Karadimitris (Imperial College, London, United Kingdom) H. Schrezenmeier (University of Ulm, Ulm, Germany) 08:00 - 08:15

0376 RITUXIMAB THERAPY FOR IMMUNE ANEMIA AND THROMBOCYTOPENIA : A BELGIAN REGISTRY RUN BY THE RED CELL SUBCOMITTEE OF THE BELGIAN SOCIETY FOR HEMATOLOGY

D. Dierickx, A. Triffet, P. Mineur, A. Kentos, A. Ferster, D. Boulet, C. Vermylen, B. Deprijk, Y. Beguin, M.F. Dresse, K. Kargar, G. Verhoef, A. Delannoy (Gasthuisberg, Leuven, Belgium) 08:15 - 08:30

0377 RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF DARBEPOETIN ALFA FOR THE TREATMENT OF ANEMIA IN CANCER PATIENTS NOT RECEIVING CHEMOTHERAPY OR RADIOTHERAPY

J.A. Glaspy, R.E. Smith, M. Aapro, H. Ludwig, T. Pintér, M. Smakal, T. Ciuleanu, L. Chen (UCLA Medical Center, Los Angeles, USA) 08:30 - 08:45

0378 SAFETY AND EFFICACY OF THE TERMINAL COMPLEMENT INHIBITOR ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: SHEPHERD PHASE III CLINICAL STUDY RESULTS

H. Schrezenmeier, L. Luzzatto, B. Rotoli, N.S. Young, J. Schubert, A. Urbano-Ispizua, L. Coyle, C. DeCastro, C.L. Fu, J.P. Maciejewski, H.A. Kroon, R.P. Rother, P. Hillmen (University Hospital Ulm, Ulm, Germany) 08:45 - 09:00

0379 THE CLINICAL BENEFIT OF ECULIZUMAB IS DEMONSTRABLE IN ALL SUBPOPULATIONS OF PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) WITH HEMOLYSIS

P. Muus, U. Dührsen, M. Elebute, P. Browne, A. Urbano-Ispizua, S. Coutre, E. Van Den Neste, R. De Paz, B. Konkle, T. Moskovits, R. Nakamura, A. Zanella, P. Hillmen, R.P. Rother, G. Socié (Radboud Univerity, Nijmegen, The Netherlands) 09:00 - 09:15

0380 THE TERMINAL COMPLEMENT INHIBITOR ECULIZUMAB REDUCES THROMBOSIS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

P. Hillmen, P. Muus, U. Dührsen, A. Risitano, J. Schubert, N.S. Young, H. Schrezenmeier, J. Szer, R.A. Brodsky, A. Hill, G. Socié, M. Bessler, S.A. Rollins, R.P. Rother, L. Bell, L. Luzzatto (Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom)

SIMULTANEOUS SESSIONS

08:00 - 09:15 hours, Room: Léhar III+IV

CYTOGENETICS AND MOLECULAR DIAGNOSTICS

Chairs: C. Mecucci (University of Perugia, Perugia, Italy) E. MacIntyre (Hôspital Necker Enfants Malade, Paris, France) 08:00 - 08:15

0381 KARYOTYPE IS AN INDEPENDENT PROGNOSTIC FACTOR IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA

A. Moorman, C.J. Harrison, G.A.N. Buck, S.M. Richards, L.M. Secker-Walker, M. Martineau, G.H. Vance, A.M. Cherry, R.R. Higgins, A.K. Fielding, L. Foroni, E. Paietta, M.S. Tallman, M.R. Litzow, P.H. Wiernik, J.M. Rowe, A.H. Goldstone, G.W. Dewald (University of Southampton, Southampton, United Kingdom) 08:15 - 08:30

0382 ETV6-NCOA2 FUSION DEFINES A NEW ENTITY OF ACUTE LEUKEMIA WITH COEXPRESSION OF T-LYMPHOID AND MYELOID MARKERS

S. Strehl, K. Nebral, M. König, H. Strobl, J. Harbott, S. Struski, B. Bielorai, M. Lessard, M. Zimmermann, O.A. Haas, S. Izraeli (CCRI, Children's Cancer Research Inst., Vienna, Austria) 08:30 - 08:45

0383 TWO DISTINCT TYPES OF GENOMIC REARRANGEMENTS INVOLVE THE C-MYB LOCUS IN HUMAN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA, INCLUDING A TRANSLOCATION T(6;7) DEFINING A NEW LEUKEMIC SUBGROUP IN VERY YOUNG CHILDREN

E. Clappier, W. Cuccuini, A. Crinquette, A. Kalota, J.M. Cayuela, W.A. Dik, A.W. Langerak, B. Montpellier, B. Nadel, P. Walrafen, O. Delattre, A. Aurias, T. Leblanc, H. Dombret, A.M. Gewirtz, A. Baruchel, F. Sigaux, J. Soulier (Hopital Saint-Louis, Paris, France) 08:45 - 09:00

0384 SYSTEMATIC EVALUATION OF COPY NUMBER ALTERATIONS IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA AND THEIR ASSOCIATION WITH TREATMENT RESPONSE

D. Steinemann, G. Cario, M. Stanulla, M. Tauscher, A. Weigmann, G. Göhring, J. Harbott, B. Radlwimmer, P. Lichter, M. Schrappe, B. Schlegelberger (Medical School Hanover, Hanover, Germany) 09:00 - 09:15

0385 CYTOPLASMIC MUTATED NUCLEOPHOSMIN DEFINES THE MOLECULAR STATUS OF A SIGNIFICANT FRACTION OF MYELOID SARCOMAS

A. Liso, D. Lenze, R. Hasserjian, S. Coupland, D. Jaehne, C. Soupir, M.P. Martelli, N. Bolli, F. Bacci, V. Pettirossi, A. Santucci, M.F. Martelli, S. Pileri, H. Stein, B. Falini (Hematology, Foggia, Italy)

SIMULTANEOUS SESSIONS

08:00 - 09:15 hours, Room: Stolz I

PLATELETS, VASCULAR BIOLOGY AND TRANSFUSION MEDICINE

Chairs: A. Falanga (Ospedali Riuniti, Bergamo, Italy) B. Mansouri (Inselspital, Bern, Switzerland) 08:00 - 08:15

0386 A PLACEBO CONTROLLED, CROSS-OVER STUDY OF CITRATE EFFECTS ON BONE METABOLISM IN HEALTH VOLUNTEERS

Y. Chen, C. Bieglmayer, H. Heinzl, P. Hoecker, M. Dettke (AKH Vienna, Vienna, Austria) 08:15 - 08:30

0387 A SMALL THROMBOPOIETIC MOLECULE NIP-004 IS EFFECTIVE FOR THE TREATMENT OF THROMBOCYTOPENIA INDUCED BY INTERFERON-ALPHA

A. Yamane, T. Nakamura, M. Ito, Y. Ohnishi, Y. Ikeda, Y. Miyakawa (School of Medicine, Keio University, Tokyo, Japan) 08:30 - 08:45

0388 IN VITRO AND IN VIVO MICROPARTICLE-ASSOCIATED ENDOTHELIAL PROTEIN C RECEPTOR CAN REVERSE PROINFLAMMATORY AND APOPTOTIC CELL SIGNALS AND EFFECTS

T. Dutt, M. Perez-Casal, C.H. Toh (University of Liverpool, Liverpool, United Kingdom) 08:45 - 09:00

0389 ENDOTHELIAL COLONY FORMING CELLS (ECFCS) FROM PATIENTS WITH CML, POLYCYTEMIA VERA (PV) AND ESSENTIAL THROMBOCYTHEMIA (ET), DERIVE FROM A STEM CELL LACKING THE DISEASE SPECIFIC MARKER

F. Frassoni, G. Piaggio, M. Corselli, F. Bertolotti, S. Pozzi, A. Parodi, B. Chiavarina, M. Sessarego, G. Fugazza, A. Garuti, A. Ibatici, A. Bacigalupo, F. Frassoni (Centro Cellule Staminali, Genoa, Italy) 09:00 - 09:15

0390 ELTROMBOPAG RAISES PLATELET COUNT AND REDUCES BLEEDING COMPARED WITH PLACEBO DURING SHORT-TERM TREATMENT IN CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA: A PHASE III STUDY

J. Bussel, A. Provan, T. Shamsi, G. Cheng, L. Kovaleva, N. Stone, B. Mayer, R. Poulin, M. Arning (Weill Medical College Cornell University, New York, USA)

SIMULTANEOUS SESSIONS

08:00 - 09:15 hours, Room: Stolz

HODGKIN'S LYMPHOMA

Chair: A. Polliack (Hadassah University Hospital, Jerusalem, Israel) J. Walewski (MSCM Institute and Cancer Center, Warsaw, Poland) 08:00 - 08:15

0391 COMBINED ESCALATED BEACOPP-ABVD THERAPY GUIDED BY PET-CT FOR ADVANCED HODGKIN'S LYMPHOMA PATIENTS WITH HIGH IPS SCORE

A. Avigdor, S. Bulvik, E. Dann, I. Levi, G. Perez-Avraham, N. Shemtov, A. Nagler, I. Ben-Bassat, A. Polliack (The Chaim Sheba Medical Center, Tel-hashomer, Israel) 08:15 - 08:30

0392 EARLY INTERIM FDG-PET DURING INTENSIFIED BEACOPP THERAPY FOR ADVANCED-STAGE HODGKIN DISEASE SHOWS A LOWER PREDICTIVE VALUE THAN DURING ABVD

A. Gallamini, S. Viviani, V. Bonfante, A. Levis, F. Di Raimondo, F. Merli, U. Vitolo, S. Bolis, P.F. Torchio (Az. Ospedaliera S. Croce e Carle, Cuneo, Italy) 08:30 - 08:45

0393 HIGH DOSE THERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION (HDT/ ASCT) IN 58 PATIENTS WITH HODGKIN’S LYMPHOMA (HL). OUTCOME AND PROGNOSTIC FACTORS

H. Galani, T.P. Vassilakopoulos, P. Tsirkinidis, M. Moschogiannis, D. Boutsis, K. Anargyrou, S. Masouridis, S. Sachanas, C. Kalpadakis, A. Sarantopoulos, E. Dimitriadou, M. Dimopoulou, N. Stavrogiannis, V. Kalotychou, E. Variamis, N.A. Viniou, S.I. Kokoris, M.P. Siakantaris, M.C. Kyrtsonis, I. Rombos, G. Vaiopoulos, G.A. Pangalis, M. Angelopoulou (University of Athens, Athens, Greece) 08:45 - 09:00

0394 EFFECT ON CLINICAL OUTCOME OF GENETIC POLYMORPHISMS IN HODGKIN LYMPHOMA PATIENTS

A. Gaya, A. Urbano-Ispizua, A. Navarro, A. Pons, P. Abrisqueta, A. Martínez, B. Gel, S. Pairet, C. Martínez, M. Granell, A. López-Guillermo, E. Montserrat, M. Monzó (Hospital Clinic of Barcelona, Barcelona, Spain) 09:00 - 09:15

0395 EARLY RESPONSE TO CHEMOTHERAPY MAY FACILITATE OMMITTING RADIOTHERAPY IN CHILDREN WITH HODGKIN’S LYMPHOMA

M.J. Jarrar, F. Bazzeh, M. Tawfiq, F. Madanat (King Hussein Cancer Center, Amman, Jordan)